mRNA

RFK Jr. is trying to dismantle mRNA research that could cure cancer and HIV—the reason is ‘revenue’

At the start of February, the U.S. Food and Drug Administration said it would not review Moderna’s application for the first mRNA-based flu vaccine. A week later, following an onslaught of public disapproval, and after Moderna agreed to split its trials into age-based segments—prioritizing older candidates—the FDA relented and said it would consider the…